Mike Wilson | 21 November 2023
The International Agency for Research on Cancer (IARC), the cancer research arm of the WHO, recently classified the common sweetener aspartame as a possible cause of cancer in humans.
The International Agency for Research on Cancer (IARC), the cancer research arm of the WHO, recently classified the common sweetener aspartame as a possible cause of cancer in humans. This work was in conjunction with the Joint Expert Committee on Food Additives. This means it could cause cancer. Aspartame is used in many food products from breakfast cereals and diet soft drinks, to some ice creams and gelatin.
However, despite the worrying headline, the threat is very small. Safety is not a major concern at doses commonly ingested. The classification assigned to aspartame is 2B, defined as ‘possibly carcinogenic to humans’. To give some idea of the company it keeps in this category, 2B also includes aloe vera, ‘carpentry and joinery’, and the use of talcum powder on the perineum, alongside a long list of chemicals.1
The classification is assigned, somewhat counterintuitively, based on levels of certainty that a risk exists, not on the actual level of that risk. There have been no changes to the recommended daily intake of aspartame, which equates to between 9 and 14 cans of soft drink per day for the average adult (approximately half of a standard bucket!), and even this level has a large built-in safety factor.
Overall, this development should not be a cause for concern.
And we shouldn’t all rush to the conclusion that sugar-sweeteners are safer than artificial ones, either. Interestingly, a separate recent study found that women who regularly drank soft drinks sweetened with sugar in the 1990s were at increased risk of liver cancer and other chronic liver diseases 20 years later.2 This relationship only existed when comparing people who drank these drinks daily against those who very rarely consumed them, and in any event the study is not powered to say whether the sugar was the cause of the later disease.
These are both interesting studies, and it is important to study links between common food additives and health. However, it is important not to exaggerate the results. Neither of these studies should cause much concern for people who take either artificial- or sugar-sweeteners in moderation.
Pacific Life Re Limited (No. 825110) is registered in England and Wales and has its registered office at Tower Bridge House, St Katharine’s Way, London, E1W 1BA. Pacific Life Re Limited is authorised and regulated by the Financial Conduct Authority and Prudential Regulatory Authority in the United Kingdom (Reference Number 202620). The material contained in this booklet is for information purposes only. Pacific Life Re gives no assurance as to the completeness or accuracy of such material and accepts no responsibility for loss occasioned to any person acting or refraining from acting on the basis of such material.
©2024 Pacific Life Re Limited. All rights reserved.
Mike Wilson
Director, Medical Analytics
Protection
When asked what opportunities life reinsurers in Asia have, Pacific Life Re's Vasan Errakiah was quick to cite demand for insurance, changing regulations and the adoption of new technologies.
Protection
Asia Insurance Review spoke to Pacific Life Re's Mr Ong Qian Hao and FWD Group's Ms Fiona Hermans to understand how strategic partnerships can effectively address these challenges and lead to successful outcomes.
Medical Advances
Read our update on the impact of mortality from COVID-19.
Medical Advances
Lung cancer is often diagnosed at a late stage leading to poor prognosis for the individual. We look at how screening could have an impact.
Underwriting & Claims
Underwriting has been going through significant transformation over the last few years and continues to accelerate at an unprecedented pace. Traditionally seen as a barrier, there is now a growing opportunity to position underwriting as a strategic asset.
Protection
Big data analytics has been instrumental for (re)insurers aiming to boost performance, efficiency, and effectiveness.
Medical Advances
From emerging drugs which battle obesity to a review of the effectiveness of new blood tests both to detect cancer and to help slow down Alzheimer’s, we hope these insights help keep you up to date with the latest in medical research.
Medical Advances
Vaping is generally considered less harmful than smoking, however longer-term risks have not had time to emerge and could prove considerable.
Medical Advances
Despite broadly improving cancer mortality, some types of the disease are increasing in incidence
Protection
Consumer Duty has put increased focus on how much value different customers get from financial products. But how well is the protection industry serving different customer groups? Who are the most underserved groups, and what can the industry do to help serve these groups better?
Underwriting & Claims
Underwriting processes, practices and philosophies are changing with faster pace than we have ever experienced before.
Medical Advances
A new generation of drugs has now well and truly arrived aiming to improve weight loss. The drugs are heavily touted by celebrities and influencers, despite many of them having no medical need to lose weight. Obesity contributes significantly to some of the most common causes of death including heart disease and cancer, as well as affecting quality of life for millions. In this article we look at these increasingly available drugs offering hope to more people with obesity. We consider their potential to broadly improve health, and their limitations.
Medical Advances
Scientists successfully conducted early-stage trials which provide hope of a future cure for some of the most severe types of multiple sclerosis (MS).
Medical Advances
The world’s largest conference dedicated to the science and treatment of cancer took place in Chicago in early June. The American Society of Clinical Oncology’s annual meeting is a popular forum at which new scientific developments are often revealed.
Medical Advances
A recent review by WHO resulted in reclassification of pituitary adenoma as described in the article
Medical Advances
In 2023 we’ve seen soaring temperatures across the globe along with devastating storms and wildfires. Why is our climate changing and what impact is it having?
Medical Advances
Welcome to our first edition of Vital Insights. Here we’ve put together a collection of articles covering some of the major issues of the day with a specific focus on how they will impact mortality and morbidity.
Medical Advances
Total deaths from dementias in high-income countries have almost quadrupled in the last 20 years, yet so far medical science has very few answers. This article looks at the recent emergence of the first drugs which may be able to modify the effects of this terrifying disease
Medical Advances
COVID-19 has stolen the limelight from other respiratory viruses in recent years. However there are plenty of other common viruses which can have serious health consequences, among them Respiratory Syncytial Virus, or RSV.
Medical Advances
A new UN report reveals optimism about a possible end to the global AIDS epidemic
Medical Advances
Vaccine technologies have continued to improve greatly in recent years. However, vaccines are little use if people refuse to use them. Here we look at the precarious position of measles, a well-known but little-understood serious condition, which is held in check in most countries only because of high vaccine uptake.
Medical Advances
The International Agency for Research on Cancer (IARC), the cancer research arm of the WHO, recently classified the common sweetener aspartame as a possible cause of cancer in humans.
Protection
Beneath the Surface report 2023 We explored some of the key drivers of sustainability for the protection market. We undertook consumer research which combined with our medical and underwriting expertise and our deep understanding of the market, enabled us to create this report.
Protection
Beneath the Surface report 2022 In this report, we analyse the current VAS landscape in the UK & Irish protection markets. Look to understand the views and experiences of customers, with the aim of assessing how much value these services are really adding today. Look at what insurers say, and consider what the future might hold for the development of VAS.